New registry aims to unlock secrets of rare cervical cancer
NCT ID NCT04723095
First seen Jun 27, 2026 · Last updated Sep 15, 2026 · Updated 2 times
Summary
This study is creating a registry of 750 people with a rare and aggressive form of cervical cancer called neuroendocrine carcinoma. Researchers will collect information from medical records to learn more about the disease, how it is treated, and what happens to patients over time. The goal is to better understand this cancer and improve future care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 750 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2013
- Expected to finish
-
Jan 2044
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with neuroendocrine cervical cancer
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with a personal history of cervical cancer with any portion of neuroendocrine component (including mixed tumors) of the following histologic subtypes: * Small cell neuroendocrine carcinoma * Large cell neuroendocrine carcinoma * Undifferentiated high-grade neuroendocrine carcinoma * Patients may be in any stage of treatment, surveillance or recurrence at the time of initial participation in the study * Patients with all stages of disease are considered eligible * Patients who do not speak English can be eligible if accompanied by an institutional interpreter * Patients who are receiving or have received treatment at any facility, including but not limited to M. D. Anderson Cancer Center are eligible * Patient may be residents of any country and be of any ethnic background * Patients who request to participate in the study, regardless of the method by which they learned of it, are eligible to participate, including, but not limited to patients who seek participation via the website * Next of kin or legal authorized representatives of patients who are deceased but had a history of neuroendocrine carcinoma (NEC) of the cervix are eligible to participate * Next of kin or legal authorized representatives of patients must read and speak English Exclusion Criteria: * Patients with other histologic subtypes of NEC of the cervix including typical and atypical carcinoid tumors
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cervical large cell neuroendocrine carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital therapy aims to tame the fear that haunts cancer survivors
- Can a smaller dose of this cancer drug still work? new trial aims to find out
- Custom-Made cancer vaccine shows promise in advanced tumors
- Experimental drug plus radiation shows promise for recurrent gynecologic cancers
- New app helps women with advanced cancer fight fear
- New radioactive 'Smart Bomb' targets Hard-to-Treat lung cancer